Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?

Current Heart Failure Reports

Volumn 6, Issue 2, 2009, Pages 112-116

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SYSTOLIC DYSFUNCTION;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 66749133394     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-009-0017-5     Document Type: Review

References (26)

1. Dickstein K, Kjekshus J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360: 752-760.
2. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349: 1893-1906. [Published erratum appears in N Engl J Med 2004, 350:203.]
3. Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358: 1547-1559.
4. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355: 1582-1587.
5. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345: 1667-1675.
6. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003, 362: 767-771.
7. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group [no authors listed]. Circulation 1998, 97: 2202-2212.
8. Rodrigues EJ, Eisenberg MJ, Pilote L: Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003, 115: 473-479.
9. Pfeffer MA, Greaves SC, Arnold JM, et al.: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997, 95: 2643-2651.
10. Pfeffer MA, Hennekens CH:RWhen a question has an answer: rationale for our early termination of the HEART Trial. Am J Cardiol 1995, 75: 1173-1175.
11. Latini R, Maggioni AP, Flather M, et al.: ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995, 92: 3132-3137.
12. Krum H, Carson P, Farsang C, et al.: Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: Results from Val-HeFT. Eur J Heart Fail 2004, 6: 937-945.
13. McMurray JJ, Young JB, Dunlap ME, et al.: Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006, 151: 985-991.
14. Lakhdar R, Al-Mallah MH, Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: A systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14: 181-188.
15. Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372: 547-553.
16. Matchar DB, McCrory DC, Orlando LA, et al.: Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008, 148: 16-29.
17. Mak G, Murphy NF, Ali A, et al.: Multiple neurohumoral modulating agents in systolic dysfunction heart failure: Are we lowering blood pressure too much? J Card Fail 2008, 14: 555-560.
18. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341: 709-717.
19. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348: 1309-1321. [Published erratum appears in N Engl J Med 2003, 348:2271.]
20. Montezano AC, Callera GE, Yogi A, et al.: Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008, 28: 1511-1518.
21. Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003, 108: 1831-1838.
22. Pitt B: Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003, 108: 1790-1794.
23. Banas J: Absence of clinical hypotension with eplerenone in post acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction. Results from Ephesus. Am J Cardiol 2006, A(Suppl): 227A.
24. McMurray J, Pitt B, Latini R, et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1: 17-24.
25. Pitt B, MNMurray J, Latini R, et al.: Heart failure: neurohormonal modulation [abstract]. Circulation 2007, 116: 2491.
26. Fisher ND, HWllenberg NK: Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005, 16: 592-599.